2026 Semaglutide improves insulin sensitivity in patients with schizophrenia and prediabetes ,, 1Semaglutide significantly improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and promoted substantial weight loss in patients with antipsychotic-induced metabolic disturbances
While Zepbound has no absolute cardiac contraindications, patients with heart failure, recent cardiovascular events, or cardiac arrhythmias require careful clinical assessment and monitoring
See your appeal options Coverage Outlook for 2026 Cigna/Express Scripts coverage for Wegovy depends on whether your employer has opted into GLP-1 benefits
Device-specific vigilance guidance: in vitro diagnostic (IVD) blood glucose monitors point of care testing and home use
Always consult a qualified prescriber before starting any prescription weight loss treatment